Retrospective cohort study assessing the long-term clinical outcomes in metastatic NSCLC patients treated by ICIs for a minimal duration of 2 years
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Feb 2023 New trial record